Search
Cytohesin-2
go.drugbank.com/bio_entities/BE0002654TargetHumansPromotes guanine-nucleotide exchange on ARF1, ARF3 and ARF6. Activates ARF factors through replacement of GDP with GTP (By similarity).
Synonyms: PH, SEC7 and coiled-coil domain-containing protein 2Padimate A
go.drugbank.com/drugs/DB11229ApprovedWithdrawnIn Europe this chemical was withdrawn in 1989 for unstated reasons and in the US it was never approved for use in sunscreens. … Padimate A is an ester derivative of PABA and an ingredient in some sunscreens.
Chikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigational[L48726] It is approved for use in patients 18 years of age and older who are at high-risk of exposure to chikungunya virus. … Infection with CHIKV causes chikungunya fever, an illness characterized by acute fever and severe, persistent arthralgia.
Cantharidin
go.drugbank.com/drugs/DB12328ApprovedInvestigational[L47496] The approval was based on positive results from 2 phase III trials, CAMP-1 and CAMP-2, where 46% and 52% of patients treated with cantharidin achieved complete molluscum clearance, respectively … [A32892] Nevertheless, it gained its first FDA approval on Jul 21, 2023, under the brand name YCANTH™ by Verrica Pharmaceuticals for the treatment of molluscum contagiosum in adult and pediatric patients
Peginterferon alfa-2b
go.drugbank.com/drugs/DB00022ApprovedInvestigationalPeginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. … Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsEmricasan
go.drugbank.com/drugs/DB05408InvestigationalIt is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis. … Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA.
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational[A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical … Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.
Levoketoconazole
go.drugbank.com/drugs/DB05667Approved[A244083, A29319, L39573] Levoketoconazole was approved by the FDA on December 30, 2021, and is currently marketed under the registered trademark RECORLEV by Xeris Pharmaceuticals, Inc.[L39563] … Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying
Categories: Sex Hormones and InsulinsRezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigationalIt can only be administered intravenously but does not reach therapeutic concentrations in the central nervous system, eye and urine. … Rezafungin is an echinocandin antifungal drug.
Categories: Amino Acids, Peptides, and ProteinsRanolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[A189234] Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. … [L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440]